Furthermore, combined treatment with a new generation pan-RAF inhibitor and trametinib has also resulted in synergistic beneficial effects in NRAS-mutant melanoma cases [141], which has brought hope to those melanoma cases hitherto orphans of a treatment. The gene discussed is RAF1; the disease is melanoma.